Epidemiological trends during the past decade suggest that although incidence of
nasopharyngeal carcinoma is gradually declining, even in endemic regions, mortality from …

Nasopharyngeal carcinoma of the undifferentiated subtype is endemic to southern China,
and patient prognosis has improved significantly over the past three decades because of …

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the
nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these …

PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to
practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy …

Background Platinum-based concurrent chemoradiotherapy is the standard of care for
patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine …

Background Patients with locoregionally advanced nasopharyngeal carcinoma have a high
risk of disease relapse, despite a high proportion of patients attaining complete clinical …

The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment
recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary …

Background The value of adding cisplatin, fluorouracil, and docetaxel (TPF) induction
chemotherapy to concurrent chemoradiotherapy in locoregionally advanced …

Nasopharyngeal carcinoma (NPC) is a disease with unique epidemiological features. The
distribution of the disease demonstrates a clear regional, racial and gender prevalence. In …

Purpose: To identify MRI-based radiomics as prognostic factors in patients with advanced
nasopharyngeal carcinoma (NPC). Experimental Design: One-hundred and eighteen …